Lovastatin Targets the USP14–Survivin Axis to Suppress Triple-Negative Breast Cancer via Ubiquitin-Mediated Proteasomal Degradation
Cells · 2025
DOI: 10.3390/cells14110816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Li Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Translational Cancer Stem Cell Research, Department of Pathophysiology, Hunan Normal University, Changsha 410013, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Survivin, Lovastatin, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of China.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2) expression, represents a therapeutic challenge due to its aggressive nature and limited treatment options. Here, we identified the cholesterol-lowering drug lovastatin (LV) as a potent apoptosis-inducing agent in TNBC. Mechanistically, LV disrupts the interaction between the deubiquitinating enzyme USP14 and Survivin, a key anti-apoptotic protein, enhancing polyubiquitination and the proteasomal degradation of Survivin. The overexpression of USP14 was found to stabilize Survivin and rescue LV-induced apoptosis and tumor suppression in vitro and in vivo, whereas USP14 silencing or inhibition with IU1 (a USP14-specific inhibitor) enhanced Survivin turnover and synergized with LV to suppress colony formation in TNBC cells. Clinical relevance was demonstrated through bioinformatic analysis and immunohistochemistry, revealing that elevated Survivin expression in TNBC tissues correlated with poor prognosis and is significantly upregulated in TNBC versus non-TNBC tissues. Our findings identify the USP14–Survivin axis as a potential therapeutic target and highlight LV as a promising candidate for TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Translational Cancer Stem Cell Research, Department of Pathophysiology, Hunan Normal University, Changsha 410013, China.
- Department of Pathology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of China
Zitieren
APA
Zhou, L., Zheng, C., Ding, S., Wang, Z., Yang, Y., Wang, Y., He, G., Fu, S., & Deng, X. (2025). Lovastatin Targets the USP14–Survivin Axis to Suppress Triple-Negative Breast Cancer via Ubiquitin-Mediated Proteasomal Degradation. Cells. https://doi.org/10.3390/cells14110816
Vancouver
Zhou L, Zheng C, Ding S, Wang Z, Yang Y, Wang Y, et al. Lovastatin Targets the USP14–Survivin Axis to Suppress Triple-Negative Breast Cancer via Ubiquitin-Mediated Proteasomal Degradation. Cells. 2025. doi:10.3390/cells14110816
BibTeX
@article{Zhou2025,
author = {Zhou, Li and Zheng, Chanjuan and Ding, Siyu and Wang, Zhiyu and Yang, Yiyuan and Wang, Yian and He, Guangchun and Fu, Shujun and Deng, Xiyun},
title = {Lovastatin Targets the USP14–Survivin Axis to Suppress Triple-Negative Breast Cancer via Ubiquitin-Mediated Proteasomal Degradation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14110816}
}
EUVIMED